CNS Pharmaceuticals holds annual shareholder meeting, elects directors
CNSP•CNS Pharmaceuticals held its annual shareholder meeting on Sept. 30, 2026. Shareholders approved raising authorized issuance under the 2020 Equity Plan by 650,000 shares to 765,061 and selected MaloneBailey, LLP as auditor for the year ending Dec. 31, 2026.
1. Shareholder approvals
Shareholders endorsed amendments to the 2020 Equity Plan, increasing authorized share issuance under the plan by 650,000 to 765,061. They also backed MaloneBailey, LLP as the company’s independent registered public accounting firm for the year ending Dec. 31, 2026.
